Rvl Pharmaceuticals Plc (RVLP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2017 | 12-2016 | 12-2006 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 34,743 | 19,559 | N/A |
| Receivables | 37,638 | 45,320 | N/A |
| Inventories | 16,947 | 19,839 | N/A |
| TOTAL | $114,826 | $94,210 | $N/A |
| Non-Current Assets | |||
| PPE Net | 31,410 | 27,730 | N/A |
| Intangibles | 772,562 | 854,106 | 0 |
| Other Non-Current Assets | 943 | 2,455 | 0 |
| TOTAL | $804,914 | $884,291 | $N/A |
| Total Assets | $919,740 | $978,500 | $N/A |
| Liabilities | |||
| Current Liabilities | |||
| Short Term Debt | 6,656 | 5,169 | N/A |
| Accounts payable and accrued liabilities | 36,070 | 34,980 | 0 |
| Accrued Expenses | 81,926 | 64,708 | N/A |
| Other current liabilities | N/A | 12,862 | N/A |
| TOTAL | $124,676 | $117,833 | $N/A |
| Non-Current Liabilities | |||
| Long Term Debt | 313,950 | 323,661 | N/A |
| Other Non-Current Liabilities | 2,382 | 4,163 | 0 |
| TOTAL | $359,280 | $395,463 | $N/A |
| Total Liabilities | $483,956 | $513,295 | $N/A |
| Shareholders' Equity | |||
| Other shareholders' equity | 435,784 | 465,205 | 0 |
| TOTAL | $435,784 | $465,205 | $N/A |
| Total Liabilities And Equity | $919,740 | $978,500 | $0 |